Popular on TelAve
- Althea Gibson Honored as Final Release in U.S. Mint's American Women Quarters Program - 168
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
- BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers
- Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
- How California Convinces Buyers Not to Purchase New Cars — and How This Hurts Dealers
- Nebraska and Starlink Local Installers working together for reliable internet
- Kudosity appoints Jules Holden to drive channel growth and expand offering in ecommerce and retail
- Own 327 Acres of American Prime Real Estate with 2 Miles Waterfront Worth In Millions for Just $7 — Worldwide Raffle Launched
- Platinum Plumbing Launches First Veteran Hot Water Heater Giveaway to Honor Local Heroes
- 2026 NBA Mock Draft: New Wave of Franchise Talent Emerges in Early Lottery Projections
Similar on TelAve
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
- New You Smile Dental Implant Center Expands Office
Metavalis Inc. Initiates Formation of Scientific Advisory Board for Non Viral Gene Therapy Asset
TelAve News/10883655
Bioengineering firm recruiting founding advisors in Lipid Physics, Hepatology, and Regulatory Affairs to guide its Smart LNP 3.0 platform and Dec 24th IP filing.
BRANSON, Mo. - TelAve -- Following the scheduled filing of foundational intellectual property for its Smart LNP 3.0 platform a novel biodegradable ionizable lipid polysarcosine conjugate Metavalis is moving to appoint four strategic partners to guide the asset through pre clinical validation and FDA Pre IND pathways.
"We are assembling a council of technical architects, not just observers," said Jordan Bekemeier, Founder of Metavalis. "Our platform is engineered to solve the Redosing Bottleneck in gene therapy for Crigler-Najjar Syndrome. We are seeking equity aligned partners who possess deep domain expertise in non viral delivery physics and regulatory strategy."
Open Advisory Seats:
Metavalis is currently accepting inquiries for the following strategic roles:
The LNP Architect (Formulation Science): Seeking Ph.D. leadership in biodegradable lipid kinetics and extra-hepatic delivery, specifically regarding Polysarcosine lipid conjugates.
The Clinical Lead (Hepatology): Seeking an M.D./Ph.D. with principal investigator experience in metabolic liver disease trials (CNS1/Urea Cycle Disorders).
More on TelAve News
The Regulatory Strategist (Compliance): Seeking former FDA CBER reviewers or regulatory consultants with specific expertise in non viral gene therapy IND applications.
The Polymer Chemist (Materials Science): Seeking expertise in Stealth polymer synthesis to replace PEG architectures.
About Metavalis Inc.
Metavalis Inc. is a biotechnology company focused on the development of non viral genetic medicines. The company integrates the Universal Constructor Protocol, a sovereign quantum neuromorphic AI architecture, to optimize biological delivery vectors.
Contact Information:
Qualified candidates and researchers interested in strategic partnership may contact the executive office directly.
You can also Apply on LinkedIn at:
https://www.linkedin.com/jobs/view/4327214946
Contact: Jordan Bekemeier, Founder & CEO
Email: jordan@metavalis.com
Website: https://metavalis.com/
Forward Looking Statements
This press release contains forward looking statements regarding the company's recruitment plans and investigational technologies. These statements are subject to risks and uncertainties.
"We are assembling a council of technical architects, not just observers," said Jordan Bekemeier, Founder of Metavalis. "Our platform is engineered to solve the Redosing Bottleneck in gene therapy for Crigler-Najjar Syndrome. We are seeking equity aligned partners who possess deep domain expertise in non viral delivery physics and regulatory strategy."
Open Advisory Seats:
Metavalis is currently accepting inquiries for the following strategic roles:
The LNP Architect (Formulation Science): Seeking Ph.D. leadership in biodegradable lipid kinetics and extra-hepatic delivery, specifically regarding Polysarcosine lipid conjugates.
The Clinical Lead (Hepatology): Seeking an M.D./Ph.D. with principal investigator experience in metabolic liver disease trials (CNS1/Urea Cycle Disorders).
More on TelAve News
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- Creative Investment Research Warns AT&T DEI Rollback Undermines Market Integrity
- TimelyBill at ITEXPO 2026: Modern Billing for Modern Telecom
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
The Regulatory Strategist (Compliance): Seeking former FDA CBER reviewers or regulatory consultants with specific expertise in non viral gene therapy IND applications.
The Polymer Chemist (Materials Science): Seeking expertise in Stealth polymer synthesis to replace PEG architectures.
About Metavalis Inc.
Metavalis Inc. is a biotechnology company focused on the development of non viral genetic medicines. The company integrates the Universal Constructor Protocol, a sovereign quantum neuromorphic AI architecture, to optimize biological delivery vectors.
Contact Information:
Qualified candidates and researchers interested in strategic partnership may contact the executive office directly.
You can also Apply on LinkedIn at:
https://www.linkedin.com/jobs/view/4327214946
Contact: Jordan Bekemeier, Founder & CEO
Email: jordan@metavalis.com
Website: https://metavalis.com/
Forward Looking Statements
This press release contains forward looking statements regarding the company's recruitment plans and investigational technologies. These statements are subject to risks and uncertainties.
Source: Metavalis
0 Comments
Latest on TelAve News
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Starlink Local Installers getting Iowa connected
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Holiday Decorations Most Likely to Cause Injuries
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
- UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
- New Book: Telecoms Customer 2035
- Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
- FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
- Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
- DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide